MedTrace Logo

Evaluation of Phage Therapy for the Treatment of Escherichia Coli and Pseudomonas Aeruginosa Wound Infections in Burned Patients

NCT02116010 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2015-07-24

No results posted yet for this study

Summary

The objective of PHAGOBURN is to assess tolerance and efficacy of local bacteriophage treatment of E. coli or P. aeruginosa wound infections in burned patients.

Conditions

  • Wound Infection

Interventions

DRUG

E. coli Phages cocktail

Use of Pherecydes Pharma Phages cocktail to treat respectively E. coli burn wound infection

DRUG

Standard of care : Silver Sulfadiazine

Use of Standard of care : Silver Sulfadiazine, to treat E. coli or P. aeruginosa infected burn wound

DRUG

P. Aeruginosa, Phages cocktail

Use of Pherecydes Pharma Phages cocktail to treat P. aeruginosa burn wound infection

Sponsors & Collaborators

  • Phaxiam Therapeutics

    lead INDUSTRY

Principal Investigators

  • Patrick Jault, MD · Service de Santé des Armées, Hopital Percy (Clamart, France)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2016-07-31

Countries

  • Belgium
  • France
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02116010 on ClinicalTrials.gov